纤维蛋白原浓缩物用于创伤相关出血:系统评价与Meta分析
该系统评价与Meta分析检索多个数据库,纳入26项研究进行系统评价,其中5项随机对照试验(n=238)进入Meta分析,评估预emptive或目标导向使用纤维蛋白原浓缩物(FC)治疗16岁以上创伤相关出血/凝血病的疗效与安全性。主要终点病死率在FC组为22%、对照组为23.4%,差异无统计学意义(RR 1.00,95%CI 0.39–2.56,P=0.99);浓缩红细胞、新鲜冰冻血浆、血小板输注需求及血栓栓塞事件在两组间亦无统计学差异。总体证据质量因偏倚风险、不精确性和不一致性被评为低至中等。作者结论认为需要进一步高质量、足够把握度的研究,并关注从进入创伤救治系统起尽早给药。
要点
- 5项RCT(n=238)Meta分析显示,创伤相关出血使用FC与对照相比病死率无统计学显著差异(FC组22% vs 对照组23.4%,RR 1.00,95%CI 0.39–2.56,P=0.99)。
- FC与对照在浓缩红细胞、新鲜冰冻血浆、血小板输注需求及血栓栓塞事件方面均无统计学差异。
- 系统评价共纳入26项研究,Meta分析仅纳入5项RCT(n=238),年龄>16岁,评估预emptive或目标导向FC用于创伤相关出血/凝血病。
- 总体证据质量因偏倚风险、不精确性和不一致性被评为低至中等。
- 作者结论认为需要进一步高质量、足够把握度的研究评估FC在创伤中的作用,并关注从进入创伤救治系统起尽早给药。
适用人群与场景
- 年龄大于16岁、发生创伤相关出血/凝血病的患者,评估预emptive或目标导向使用纤维蛋白原浓缩物(FC)。
研究设计与关键结果
- 系统评价共纳入26项研究;Meta分析纳入5项随机对照试验,共n=238例。
- 主要终点病死率:FC组22% vs 对照组23.4%,RR 1.00(95%CI 0.39–2.56),P=0.99,无统计学显著差异。
- FC与对照在浓缩红细胞、新鲜冰冻血浆、血小板输注需求及血栓栓塞事件方面均无统计学差异。
- 总体证据质量因偏倚风险、不精确性和不一致性被评为低至中等。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,证据等级为level II。
- Meta分析仅纳入随机对照试验,采用Cochrane方法学进行偏倚风险评估,并遵循PRISMA指南。
- 总体证据质量因偏倚风险、不精确性和不一致性被评为低至中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为需要进一步高质量、足够把握度的研究评估FC在创伤中的作用,并关注从进入创伤救治系统起尽早给药。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma-induced coagulopathy contributes to significant morbidity and mortality in patients who experience trauma-related bleeding. This study aimed to synthesize the evidence supporting the efficacy and safety of preemptive and goal-directed fibrinogen concentrate (FC) in the management of trauma-related hemorrhage.
METHODS: PubMed, Medline, EMBASE, Web of Science, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform were systematically searched. All trial designs, except individual case reports, which evaluated the preemptive or goal-directed use of FC for trauma-related bleeding/coagulopathy, in patients older than 16 years, were included in the systematic review. For the included randomized controlled trials comparing FC with control, meta-analysis was performed and a risk-of bias-assessment was completed using the Cochrane Methodology and Preferred Reporting Items Systematic Reviews and Meta-analysis guidelines.
RESULTS: A total of 2,743 studies were identified; 26 were included in the systematic review, and 5 randomized controlled trials (n = 238) were included in the meta-analysis. For the primary outcome of mortality, there was no statistically significant difference between the groups, with 22% and 23.4% in the FC and comparator arms, respectively (risk ratio, 1.00 [95% confidence interval, 0.39 to 2.56]; p = 0.99). In addition, there was no statistical difference between FC and control in packed red blood cell, fresh frozen plasma, or platelet transfusion requirements, and thromboembolic events. Overall, the quality of evidence was graded as low to moderate because of concerns with risk of bias, imprecision, and inconsistency.
CONCLUSION: Further high-quality, adequately powered studies are needed to assess the impact of FC in trauma, with a focus on administration as early as possible from the point of entry into the trauma system of care.
LEVEL OF EVIDENCE: Systematic review and Meta-analysis, level II.
参考来源
- Stabler SN, Li SS, Karpov A, et al. Use of fibrinogen concentrate for trauma-related bleeding: A systematic-review and meta-analysis. J Trauma Acute Care Surg. 2020. PMID: 32890340. doi:10.1097/TA.0000000000002920
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。